New cancer drug begins human testing in patients out of options
NCT ID NCT05387928
Summary
This first-in-human study tested a new drug called KL340399 injection in 21 patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for any early signs that it might help shrink tumors. Researchers tested increasing doses to determine the highest amount patients could tolerate without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.